The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional protein-based option for the coronavirus -- is sowing uncertainty about updates to other vaccines, too.
Novavax said on Monday that the Food and Drug Administration was asking the company to run a new clinical trial of its vaccine after the agency grants full approval.
But a weekend post on social media by FDA Commissioner Marty Makary suggested the prospect of needing a new trial before the shots' yearly strain update -- something unlikely to be possible before fall.
The story "FDA review of Novavax Covid-19 vaccine sparks uncertainty about other shots" has 809 words across 28 sentences, which will take approximately 4 - 7 minutes for the average person to read.
Which news outlet covered this story?
The story "FDA review of Novavax Covid-19 vaccine sparks uncertainty about other shots" was covered 19 hours ago by Business Standard, a news publisher based in India.
How trustworthy is 'Business Standard' news outlet?
Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news.
The outlet is headquartered in India and publishes an average of 307 news stories per day.
It's most recent story was published 2 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
